Korean Post-marketing Surveillance for Sprycel®
NCT01464047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 670
Last updated 2016-04-27
Summary
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.
Conditions
- Leukemia, Myelomonocytic, Chronic
- Leukemia-Lymphoma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2015-08-31
- Completion
- 2015-08-31
Countries
- South Korea
Study Locations
More Related Trials
-
A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome
NCT01497145 ·Status: COMPLETED ·Phase: PHASE2
-
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
NCT04150471 ·Status: UNKNOWN
-
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
NCT00058747 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
NCT02389972 ·Status: COMPLETED
-
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00449761 ·Status: TERMINATED ·Phase: PHASE2
-
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
NCT04067518 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
NCT00481247 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788639 ·Status: RECRUITING
-
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
NCT02920541 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
NCT01357655 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082 ·Status: RECRUITING ·Phase: PHASE3
-
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
NCT00257647 ·Status: COMPLETED
-
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
NCT06430736 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization
NCT02975115 ·Status: UNKNOWN
-
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
NCT01961882 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
NCT00895297 ·Status: TERMINATED ·Phase: PHASE2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
NCT04312841 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
NCT00761449 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia
NCT01556386 ·Status: COMPLETED
-
2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
NCT04953780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
NCT03370185 ·Status: WITHDRAWN ·Phase: PHASE2
-
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
NCT02920697 ·Status: COMPLETED ·Phase: PHASE1
-
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
NCT01493414 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
NCT07075406 ·Status: COMPLETED